Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Navigencis (Foster City, CA) a commercial-stage personalized genomics company, closed a $18M Series C financing. Participants include Procter & Gamble, Kleiner Perkins Caufield & Byers and Mohr Davidow Ventures.

Pulmonx (Redwood City, CA) a commercial-stage medical device company focused on minimally invasive devices for the diagnosis and treatment of COPD and other pulmonary disorders, closed a $32M Series C financing. Participants include HealthCap, Kleiner Perkins Caufield & Byers, De Novo Ventures, Latterell Venture Partners, MedVenture Associates, Montreux Equity Partners and Posco BioVentures.

Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications, closed a $8M Series B financings, bringing the total round to $40M. Participants include New Enterprise Associates, Bay City Capital, Amgen Ventures, Astellas Venture Partners, MPM Capital and Kleiner Perkins Caufield and Byers. Note: 2009 Year-in-Review Trend Analysis Coming 15 […]

Spinal Modulation (Menlo Park, CA) a development-stage medical device company focused on a spinal cord stimulator system for treating chronic intractable pain, closed a $27.4M Series C financing. Participants include Johnson & Johnson Development Corp., DFJ InCube Ventures, Raffles Venture Partners, DeNovo Ventures, DFJ ePlanet, Kleiner Perkins Caufield & Byers and MedVenture. Note: 2009 Year-in-Review […]

Tethys Bioscience (Emeryville, CA) a commercial-stage diagnostics company focused on type II diabetes risk assessment through the measurement of multiple biomarkers, closed a $25M Series D financing. Participants include Capital AG, Wasatch Advisors, Mohr Davidow Ventures, Kleiner Perkins Caulfield & Byers and Intel Capital. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications. Participants include Bay City Capital, Amgen Ventures, Astellas Venture Management, MPM Capital and Kleiner Perkins Caufield and Byers. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Nodality (San Francisco, CA) a development-stage molecular diagnostics company focused on hematological malignancies and autoimmune disorders, closed a $3.5M Series C financing. Participants have included Kleiner Perkins Caufield & Byers, Maverick Capital, Pfizer and TPG Ventures. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

« Previous Page  Next Entries »

to top of page...